Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IGM Biosciences Inc (IGMS)
NASDAQ:IGMS
IGM Biosciences (IGMS) Stock Price & Analysis
273 Followers
IGMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.81 - $17.70
Previous Close$6.79
Volume134.28K
Average Volume (3M)330.79K
Market Cap
$400.77M
Enterprise Value$147.93M
Total Cash (Recent Filing)$293.77M
Total Debt (Recent Filing)$40.93M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Aug 05, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding59,023,575
10 Day Avg. Volume282,449
30 Day Avg. Volume330,790
Standard Deviation0.28
R-Squared0.00168
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.12
Price to Sales (P/S)494.06
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-321.59
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$21.17Price Target Upside230.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
IGM Biosciences News
PremiumCompany Announcements
IGM Biosciences Stockholders Endorse Governance and Compensation Plans
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRecent internal research suggests that the company's DR5-targeting therapy may spare the liver from toxicity while effectively targeting tumors, offering a potential therapeutic advantage.
Financial StrengthIGM ended 1Q24 with roughly $293.8M in cash; this balance sheet strength should be sufficient to provide an operational runway into 2Q26.
Stock PerformanceIGMS shares are trading up significantly following Biogen’s acquisition of Human Immunology Biosciences.
Bears Say
Acquisition ImpactAnalyst sees limited positive read-through from the HI-Bio acquisition.
Development And Approval RisksRisks include, but are not limited to: inability to achieve a best-in-class profile for IGM-8444; failure to obtain approval for IGM-8444 or imvotamab; setbacks with other candidates; inability to achieve competitive manufacturing efficiencies with IgM-based antibodies; and medium to long-term dilution risk.
Partnership TerminationSanofi drops oncology-focused portion of collaboration.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IGMS FAQ
What was IGM Biosciences Inc’s price range in the past 12 months?
IGM Biosciences Inc lowest stock price was $3.81 and its highest was $17.70 in the past 12 months.
What is IGM Biosciences Inc’s market cap?
Currently, no data Available
When is IGM Biosciences Inc’s upcoming earnings report date?
IGM Biosciences Inc’s upcoming earnings report date is Aug 05, 2024 which is in 33 days.
How were IGM Biosciences Inc’s earnings last quarter?
IGM Biosciences Inc released its earnings results on May 08, 2024. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.805 by -$0.025.
Is IGM Biosciences Inc overvalued?
According to Wall Street analysts IGM Biosciences Inc’s price is currently Undervalued.
Does IGM Biosciences Inc pay dividends?
IGM Biosciences Inc does not currently pay dividends.
What is IGM Biosciences Inc’s EPS estimate?
IGM Biosciences Inc’s EPS estimate is -$0.04.
How many shares outstanding does IGM Biosciences Inc have?
IGM Biosciences Inc has 33,636,593 shares outstanding.
What happened to IGM Biosciences Inc’s price movement after its last earnings report?
IGM Biosciences Inc reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.805. Following the earnings report the stock price went up 8.351%.
Which hedge fund is a major shareholder of IGM Biosciences Inc?
Among the largest hedge funds holding IGM Biosciences Inc’s share is Baker Bros Advisors LP. It holds IGM Biosciences Inc’s shares valued at 39M.
---
IGM Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.17 (230.78% Upside)
$21.17 (230.78% Upside)
Blogger Sentiment
Neutral
IGMS Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 413.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $86.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.43%
12-Months-Change
Fundamentals
Return on Equity
-118.26%
Trailing 12-Months
Asset Growth
-18.72%
Trailing 12-Months
Company Description
IGM Biosciences Inc
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
---
IGMS Earnings Call
Q4 2023
0:00 / 0:00
---
IGMS Stock 12 Month Forecast
Average Price Target
$21.17
▲(230.78% Upside)
Technical Analysis
Best Analysts Covering IGMS
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+18.21%
reiterated a buy rating 3 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +18.21% per trade.
---